September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Using the Extracellular Matrix to Engineer Stem Cell Therapies for Ocular Disease
Author Affiliations & Notes
  • Dennis O Clegg
    Univ of California-Santa Barbara, Santa Barbara, California, United States
  • Footnotes
    Commercial Relationships   Dennis Clegg, Regenerative Patch Technologies (I)
  • Footnotes
    Support  CIRM Grant DR3-07438, US Army Research Office Grant W911NF-09-0001, The Garland Initiative for Vision, and a Wynn-Gund Grant from the Foundation Fighting Blindness
Investigative Ophthalmology & Visual Science September 2016, Vol.57, No Pagination Specified. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Dennis O Clegg; Using the Extracellular Matrix to Engineer Stem Cell Therapies for Ocular Disease. Invest. Ophthalmol. Vis. Sci. 2016;57(12):No Pagination Specified. doi:

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Presentation Description : One promising option for the treatment of ocular disease is to develop cellular therapies using RPE and neural retinal cells derived from pluripotent stem cells. One strategy for treating dry age related macular degeneration is to implant differentiated, polarized monolayers of hESC-RPE or iPS-RPE on a extracellular matrix-based scaffold, whereby cells are provided with a supportive substrate to stimulate cell survival, differentiation and function. We describe recent efforts develop tissue constructs to replace ocular tissue and translate them to the clinic.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.